Moreover, the elimination of effective therapeutic targets (PR, ER, and HER2) due to the lack of expression in TNBC is associated with adverse effects on diagnosis and treatment, making TNBC the most aggressive BC subtype, highly metastatic, and with poor overall survival rates in about 15% of all BC cases [3]. Here, ERBB2 is linked to breast cancer.